ZA975470B - Insulin preparations containing naci. - Google Patents
Insulin preparations containing naci.Info
- Publication number
- ZA975470B ZA975470B ZA9705470A ZA975470A ZA975470B ZA 975470 B ZA975470 B ZA 975470B ZA 9705470 A ZA9705470 A ZA 9705470A ZA 975470 A ZA975470 A ZA 975470A ZA 975470 B ZA975470 B ZA 975470B
- Authority
- ZA
- South Africa
- Prior art keywords
- insulin preparations
- preparations containing
- containing naci
- insulin
- naci
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
- 102000004877 Insulin Human genes 0.000 title abstract 2
- 108090001061 Insulin Proteins 0.000 title abstract 2
- 229940125396 insulin Drugs 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK68596 | 1996-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA975470B true ZA975470B (en) | 1997-12-22 |
Family
ID=8096378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9705470A ZA975470B (en) | 1996-06-20 | 1997-06-20 | Insulin preparations containing naci. |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP0921812B2 (cs) |
| JP (2) | JP4404380B2 (cs) |
| KR (1) | KR100451778B1 (cs) |
| CN (1) | CN1120019C (cs) |
| AT (1) | ATE208208T1 (cs) |
| AU (1) | AU720484B2 (cs) |
| BR (1) | BR9709845B1 (cs) |
| CA (1) | CA2258097C (cs) |
| CZ (1) | CZ297937B6 (cs) |
| DE (1) | DE69708121T3 (cs) |
| DK (1) | DK0921812T4 (cs) |
| ES (1) | ES2167751T5 (cs) |
| HU (1) | HU228094B1 (cs) |
| IL (2) | IL127366A0 (cs) |
| NO (1) | NO324430B1 (cs) |
| PL (1) | PL189964B1 (cs) |
| PT (1) | PT921812E (cs) |
| RU (1) | RU2182015C2 (cs) |
| UA (1) | UA49890C2 (cs) |
| WO (1) | WO1997048414A1 (cs) |
| ZA (1) | ZA975470B (cs) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002500196A (ja) * | 1998-01-09 | 2002-01-08 | ノヴォ ノルディスク アクティーゼルスカブ | 安定化させたインスリン組成物 |
| ATE259653T1 (de) * | 1998-11-18 | 2004-03-15 | Novo Nordisk As | Stabile wässrige insulinzubereitungen ohne phenol und kresol |
| US6489292B1 (en) | 1998-11-18 | 2002-12-03 | Novo Nordisk A/S | Stable aqueous insulin preparations without phenol and cresol |
| DK1146896T3 (da) * | 1999-01-26 | 2002-09-02 | Lilly Co Eli | Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger |
| WO2000059499A1 (en) * | 1999-04-05 | 2000-10-12 | Verteletsky, Pavel Vasilievich | Use of succinic acid or salts thereof for the treatment of diabetes mellitus and wound healing |
| EP1523993A1 (en) * | 1999-12-16 | 2005-04-20 | Eli Lilly & Company | Polypeptide compositions with improved stability |
| AU777570B2 (en) * | 1999-12-16 | 2004-10-21 | Eli Lilly And Company | Polypeptide compositions with improved stability |
| US7022674B2 (en) | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
| RU2389503C2 (ru) | 2004-10-05 | 2010-05-20 | Ново Нордиск А/С | Фармацевтический препарат, содержащий кристаллический инсулин и растворенный инсулин |
| RU2288000C1 (ru) * | 2005-04-27 | 2006-11-27 | Институт нефтехимического синтеза им. А.В. Топчиева РАН (ИНХС РАН) | Раствор инсулина для перорального введения |
| LT2349324T (lt) | 2008-10-17 | 2017-12-27 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
| PL2498802T3 (pl) | 2009-11-13 | 2015-06-30 | Sanofi Aventis Deutschland | Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę |
| PT3345593T (pt) | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina |
| KR101823320B1 (ko) | 2010-08-30 | 2018-01-31 | 사노피-아벤티스 도이칠란트 게엠베하 | 제２형 진성 당뇨병 치료용 약제를 제조하기 위한 ａｖｅ００１０의 용도 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| DK2750699T3 (en) | 2011-08-29 | 2015-10-26 | Sanofi Aventis Deutschland | A pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| CN104870469A (zh) * | 2012-12-26 | 2015-08-26 | 沃克哈特有限公司 | 药物组合物 |
| TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| JP2020114861A (ja) * | 2014-01-09 | 2020-07-30 | サノフイＳａｎｏｆｉ | インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤 |
| RU2016132386A (ru) | 2014-01-09 | 2018-02-14 | Санофи | Стабилизированные фармацевтические составы без глицерина на основе инсулиновых аналогов и/или инсулиновых производных |
| JP2020143105A (ja) * | 2014-01-09 | 2020-09-10 | サノフイＳａｎｏｆｉ | インスリンアスパルトの安定化された医薬製剤 |
| SG11201604706TA (en) * | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin aspart |
| JP6641280B2 (ja) | 2014-01-09 | 2020-02-05 | サノフイＳａｎｏｆｉ | インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤 |
| TN2017000235A1 (en) | 2014-12-12 | 2018-10-19 | Sanofi Aventis Deutschland | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| AU2021379990A1 (en) * | 2020-11-16 | 2023-06-29 | W. L. Gore & Associates, Inc. | Formulations, methods, and pre-filled multi-dose injection devices without cloud point |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK116527B (da) * | 1967-03-01 | 1970-01-19 | Nordisk Insulinlab | Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse. |
| SU1528496A1 (ru) * | 1972-10-17 | 1989-12-15 | Днепропетровский Научно-Исследовательский Институт Гастроэнтерологии | Дегидратирующее средство |
| US4783441A (en) † | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
| US4439181A (en) * | 1981-01-26 | 1984-03-27 | Regents Of The University Of Minnesota | Polyol-hormone mixture for use in chronic parenteral hormone administration |
| AU550068B2 (en) † | 1981-03-10 | 1986-02-27 | Novo Nordisk A/S | Zinc insulin stabilized with calcium or magnesium salts |
| US4839341A (en) * | 1984-05-29 | 1989-06-13 | Eli Lilly And Company | Stabilized insulin formulations |
| PH25772A (en) * | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| PT93057B (pt) * | 1989-02-09 | 1995-12-29 | Lilly Co Eli | Processo para a preparacao de analogos da insulina |
| DE10199011I2 (de) * | 1993-06-21 | 2004-10-14 | Novo Nordisk As | ASP-B28-Insulinkristalle. |
| NZ273285A (en) * | 1993-09-17 | 1997-10-24 | Novo Nordisk As | Insulin derivatives and compositions thereof |
| US5474978A (en) * | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US5461031A (en) * | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
-
1997
- 1997-06-19 IL IL12736697A patent/IL127366A0/xx active IP Right Grant
- 1997-06-19 DK DK97928123.5T patent/DK0921812T4/da active
- 1997-06-19 JP JP50212998A patent/JP4404380B2/ja not_active Expired - Lifetime
- 1997-06-19 CZ CZ0395698A patent/CZ297937B6/cs not_active IP Right Cessation
- 1997-06-19 ES ES97928123T patent/ES2167751T5/es not_active Expired - Lifetime
- 1997-06-19 HU HU9904031A patent/HU228094B1/hu unknown
- 1997-06-19 RU RU99101068/14A patent/RU2182015C2/ru active
- 1997-06-19 AU AU32536/97A patent/AU720484B2/en not_active Expired
- 1997-06-19 UA UA98126686A patent/UA49890C2/uk unknown
- 1997-06-19 AT AT97928123T patent/ATE208208T1/de active
- 1997-06-19 PL PL97330763A patent/PL189964B1/pl unknown
- 1997-06-19 BR BRPI9709845-0A patent/BR9709845B1/pt not_active IP Right Cessation
- 1997-06-19 CA CA2258097A patent/CA2258097C/en not_active Expired - Lifetime
- 1997-06-19 EP EP97928123A patent/EP0921812B2/en not_active Expired - Lifetime
- 1997-06-19 KR KR10-1998-0710429A patent/KR100451778B1/ko not_active Expired - Lifetime
- 1997-06-19 WO PCT/DK1997/000268 patent/WO1997048414A1/en active IP Right Grant
- 1997-06-19 CN CN97195648A patent/CN1120019C/zh not_active Expired - Lifetime
- 1997-06-19 DE DE69708121T patent/DE69708121T3/de not_active Expired - Lifetime
- 1997-06-19 PT PT97928123T patent/PT921812E/pt unknown
- 1997-06-20 ZA ZA9705470A patent/ZA975470B/xx unknown
-
1998
- 1998-12-02 IL IL127366A patent/IL127366A/en not_active IP Right Cessation
- 1998-12-18 NO NO19985981A patent/NO324430B1/no not_active IP Right Cessation
-
2009
- 2009-05-07 JP JP2009112970A patent/JP2009235075A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA975470B (en) | Insulin preparations containing naci. | |
| AU635358B2 (en) | Transdermal administration of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole | |
| DE69737995D1 (de) | INSULINPREPARATION MIT MAnnitol | |
| ATE177757T1 (de) | Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17 | |
| ATE270557T1 (de) | Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen | |
| ZA200102105B (en) | Stable concentrated insulin preparations for pulmonary. | |
| CA2075060A1 (en) | Novel vehicle gases and their use in medical preparations | |
| UA39158C2 (uk) | Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі | |
| ES2162951T3 (es) | Estabilizacion de composiciones de prostaglandina. | |
| GB9806632D0 (en) | Peptide factor | |
| AU5186799A (en) | Peptides of il-2 and derivatives thereof and their use as therapeutic agents | |
| NO20012249D0 (no) | Faststoffsammensetning inneholdende D-mannitol og cerivastatin samt anvendelse av faststoffsammensetning forfremstilling av farmasöytisk preparat | |
| ATE92542T1 (de) | Azeotropaehnliche zusammensetzungen von 1,1dichlor-2,2,2-trifluoraethan und 1,1-dochlor-1fluor|than. | |
| AU631334B2 (en) | 2-substituted n,n'-ditrimethoxybenzoyl piperazines, and therapeutic compositions containing them | |
| ES2152315T3 (es) | Xamoneline tartrato. | |
| ATE196914T1 (de) | Lh-rh analoge mit starrer konformation, deren verwendungen und pharmazeutische zusammensetzungen | |
| ATE145824T1 (de) | Aerosolformulierung enthaltend fusafungin | |
| ATE204286T1 (de) | Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge | |
| FR2707492B1 (fr) | Nouvelles compositions cosmétiques ou dermatologiques renfermant les ribosomes, préparation des ribosomes, préparation desdites compositions et leur application. | |
| FI954401A7 (fi) | Atseotrooppimaiset koostumukset, joissa on 1,1,1,2,3,3,3-heptafluoripr opaania ja 1,1-difluorietaania |